Investors & News

Investor Relations

Webcast ImageWebcast
Q3 2017 Ascendis Pharma Earnings Conference Call (Replay)
11/16/17 at 1:30 p.m. PT
Q3 2017 Ascendis Pharma Earnings Conference Call
Thursday, November 16, 2017 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Ascendis Pharma at the Stifel 2017 Healthcare Conference (Replay)
11/14/17 at 3:30 p.m. ET
Ascendis Pharma at the Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017 3:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$36.94
Change (%) Stock is Up 0.19 (0.52%)
Volume366,399
Data as of 11/17/17 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $36.94 with a 52 week high of $42.00 and a 52 week low of $19.21.
Recent NewsMore >>
16/Nov/2017
Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results
02/Nov/2017
Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference Call on November 16
31/Oct/2017
Ascendis Pharma A/S Announces Participation in Two Upcoming Investor Conferences
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma
E-mail: ir@ascendispharma.com

Data provided by Nasdaq. Minimum 15 minutes delayed.